EcoDrugPlus

Potassium Inwardly Rectifying Channel Subfamily J Member 2

Ensembl ID : ENSFHEG00000011010
Gene Symbol: KCNJ2
3 Cross references
201 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 2

Ensembl ID : ENSFHEG00000012591
Gene Symbol: KCNJ2
1 Cross references
197 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 3

Ensembl ID : ENSFHEG00000021619
Gene Symbol: KCNJ3
1 Cross references
222 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 5

Ensembl ID : ENSFHEG00000016981
Gene Symbol: KCNJ5
3 Cross references
209 Possible Orthologues:

Potassium Two Pore Domain Channel Subfamily K Member 2

Ensembl ID : ENSFHEG00000010197
Gene Symbol: KCNK2
3 Cross references
221 Possible Orthologues:

Potassium Two Pore Domain Channel Subfamily K Member 3

Ensembl ID : ENSFHEG00000022927
Gene Symbol: KCNK3
3 Cross references
203 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily A Member 5

Ensembl ID : ENSFHEG00000023195
Gene Symbol: KCNA5
2 Cross references
170 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily D Member 3

Ensembl ID : ENSFHEG00000000417
Gene Symbol: KCND3
4 Cross references
190 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily D Member 3-Like

Ensembl ID : ENSFHEG00000019776
Gene Symbol: LOC105935898
3 Cross references
194 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily H Member 2

Ensembl ID : ENSFHEG00000008936
Gene Symbol: KCNH2
3 Cross references
186 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Kqt Member 2-Like

Ensembl ID : ENSFHEG00000010323
Gene Symbol: LOC105925910
3 Cross references
184 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Kqt Member 4-Like

Ensembl ID : ENSFHEG00000008141
Gene Symbol: LOC105920704
2 Cross references
200 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).